Irinophore C™, a lipid nanoparticulate formulation of irinotecan, improves vascular function, increases the delivery of sequentially administered 5-FU in HT-29 tumors, and controls tumor growth in patient derived xenografts of colon cancer

Publication | Closed Access

DOI

Citations

References

2014

Year

Robert W. Neijzen, May Q. Wong, Navdeep Gill, He Wang, Tamanna Karim, Malathi Anantha, Dita Strutt, Dawn Waterhouse, Marcel B. Bally, Isabella T. Tai,

Journal of Controlled Release

Tumor BiologyNanomedicineDrug TargetingOncologyNanotherapeuticsVascular FunctionEngineeringMedicineTherapeutic NanomaterialsControls Tumor GrowthDrug Delivery SystemsTumor TargetingIrinophore C™Biomedical EngineeringAnti-cancer AgentPharmacologyCancer Research